
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Compumedics Limited is a medical devices business based in Australia. Compumedics shares (CMP) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Compumedics has a trailing 12-month revenue of around $35.1 million.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $0.25 - $0.735 |
---|---|
50-day moving average | $0.4603 |
200-day moving average | $0.4519 |
Target price | $1.9 |
PE ratio | 22.7273 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.019 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Compumedics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Compumedics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Compumedics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 23x. In other words, Compumedics shares trade at around 23x recent earnings.
That's relatively low compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Compumedics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $266,000 (£145,019).
The EBITDA is a measure of a Compumedics's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $35.1 million |
---|---|
Gross profit TTM | $18 million |
Return on assets TTM | -0.55% |
Return on equity TTM | -23.78% |
Profit margin | -16.65% |
Book value | 0.123 |
Market capitalisation | $79.7 million |
TTM: trailing 12 months
We're not expecting Compumedics to pay a dividend over the next 12 months.
Over the last 12 months, Compumedics's shares have ranged in value from as little as $0.25 up to $0.735. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Compumedics's is 0.9479. This would suggest that Compumedics's shares are less volatile than average (for this exchange).
Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somté PSG; Siesta 802, an ambulatory recording device; Grael PSG; and Somté, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; ProFusion neXus 360, a Web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, and summit IP products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was founded in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited is a subsidiary of D & DJ Burton Holdings Pty Ltd.
You can now invest as little as 1 cent into Australian, NZ and US shares. Here's why that's a game changer.
Everything we know about the Didi Chuxing IPO, plus information on how to buy in.
Robinhood is set to go public as soon as June. Here's what you need to do to buy in from Australia.
We explain everything you need to make your own retro arcade machine, built around the super-flexible Raspberry Pi.
Beat the banks, find the best exchange rates and avoid fees when you send money abroad from Australia.
All the key info you need to know to sell shares you inherited or received as a gift.
Steps to owning and managing Roblox shares.
Everything we know about the Deliveroo IPO, plus information on how to buy in.
Steps to owning and managing Zebit shares.